Mounjaro European Union - Greek - EMA (European Medicines Agency)

mounjaro

eli lilly nederland b.v. - tirzepatide - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 και 5.

Locametz European Union - Greek - EMA (European Medicines Agency)

locametz

novartis europharm limited  - gozetotide - Απεικόνιση ραδιονουκλεϊδίων - Διαγνωστικά ραδιοφαρμακευτικά προϊόντα - Αυτό το φαρμακευτικό προϊόν προορίζεται μόνο για διαγνωστική χρήση. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Pluvicto European Union - Greek - EMA (European Medicines Agency)

pluvicto

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - Νεοπλάσματα Του Προστάτη, Ο Ευνουχισμός Ανθεκτικό - Θεραπευτικά ραδιοφαρμακευτικά προϊόντα - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

MYDOFLEX 150MG FILM COATED TABLETS Cyprus - Greek - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

mydoflex 150mg film coated tablets

m k stavrinos ltd (0000003059) 3 eracleous, lefkosia, 1501, 21074 - tolperisone hydrochloride - film coated tablets - 150mg - tolperisone hydrochloride (0003644619) 150mg - tolperisone

EFLUELDA 60MCG/DOSE SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Cyprus - Greek - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

efluelda 60mcg/dose suspension for injection in pre-filled syringe

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238); a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227); b/victoria - b/michigan/01/2021 (wild type virus); b/phuket/3073/2013 – like strain (b/phuket/3073/2013, wild type) [yamagata lineage] - suspension for injection in pre-filled syringe - 60mcg/dose - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238) (8000004883) 60ug; a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) (8000004863) 60ug; b/victoria - b/michigan/01/2021 (wild type virus) (8000004875) 60ug; b/phuket/3073/2013 – like strain (b/phuket/3073/2013, wild type) [yamagata lineage] (8000004705) 60ug

VAXIGRIP (ΑΝΤΙΓΡΙΠΠΙΚΟ ΓΙΑ ΠΑΙΔΙΑ) (7,5+7,5+7,5)MCG/0,25ML PF.SYR (1 δόση) INJ.SU.PFS Greece - Greek - Εθνικός Οργανισμός Φαρμάκων

vaxigrip (αντιγριππικο για παιδια) (7,5+7,5+7,5)mcg/0,25ml pf.syr (1 δόση) inj.su.pfs

vianex a.e. - influenza, inactivated, split virus or surface antigen - ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ - (7,5+7,5+7,5)mcg/0,25ml pf.syr (1 δόση) - ΕΜΒΟΛΙΑ

VAXIGRIP TETRA® INJ.SU.PFS (15+15+15+15)MCG/0.5ML PF.SYR (1 δόση). Greece - Greek - Εθνικός Οργανισμός Φαρμάκων

vaxigrip tetra® inj.su.pfs (15+15+15+15)mcg/0.5ml pf.syr (1 δόση).

sanofi pasteur europe, france 14 espace henry vallee, 69007 lyon +33 437 28 40 00 - a/victoria/2570/2019 (h1n1) pdm09 - like strain (a/victoria/2570/2019, ivr-215); a/cambodia/e0826360/2020 (h3n2) - like strain a/tasmania/503/2020, ivr-221); b/washington/02/2019 - like strain (b/victoria/705/2018/bvr-11); b/phuket/3073/2013 – like strain(b/phuket/3073/2013, wild type) - inj.su.pfs (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - (15+15+15+15)mcg/0.5ml pf.syr (1 δόση). - a/victoria/2570/2019 (h1n1) pdm09 - like strain (a/victoria/2570/2019, ivr-215) 15mcg; a/cambodia/e0826360/2020 (h3n2) - like strain a/tasmania/503/2020, ivr-221) 15mcg; b/washington/02/2019 - like strain (b/victoria/705/2018/bvr-11) 15mcg; b/phuket/3073/2013 – like strain(b/phuket/3073/2013, wild type) 15mcg - influenza, purified antigen

VAXIGRIP SOLUTION FOR INJECTION Cyprus - Greek - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

vaxigrip solution for injection

sanofi pasteur sa - a/california/7/2009 (h1n1), a/texas/50/2012 (h3n2) b/massachusetts/02/2012 - solution for injection - 8000004241 - a/california/7/2009 (h1n1) - 15 ug; 8000004436 - a/texas/50/2012 (h3n2) - 15 ug; 8000004437 - b/massachusetts/02/2012 - 15 ug - influenza, purified antigen

VAXIGRIPTETRA 15MCG/DOSE SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE Cyprus - Greek - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

vaxigriptetra 15mcg/dose suspension for injection in pre-filled syringe

sanofi pasteur. (0000010487) 14 espace henry vallee, lyon, 69007 - a/guangdong-maonan/swl1536/2019 (h1n1)pdm09-like strain (a/guangdong- maonan/swl1536/2019, cnic-1909); a/hong kong/2671/2019 (h3n2)-like strain (a/hong kong/2671/2019, ivr-208); b/washington/02/2019-like strain (b/washington/02/2019, wild type); b/phuket/3073/2013-like strain (b/phuket/3073/2013, wild type) - suspension for injection in pre-filled syringe - 15mcg/dose - a/guangdong-maonan/swl1536/2019 (h1n1)pdm09-like strain (a/guangdong- maonan/swl1536/2019, cnic-1909) (8000004814) 15ug; a/hong kong/2671/2019 (h3n2)-like strain (a/hong kong/2671/2019, ivr-208) (8000004815) 15ug; b/washington/02/2019-like strain (b/washington/02/2019, wild type) (8000004816) 15ug; b/phuket/3073/2013-like strain (b/phuket/3073/2013, wild type) (8000004817) 15ug - influenza, purified antigen

EFLUELDA® INJ.SU.PFS (60+60+60+60)MCG/0.7ML PF.SYR (1 ΔΟΣΗ) Greece - Greek - Εθνικός Οργανισμός Φαρμάκων

efluelda® inj.su.pfs (60+60+60+60)mcg/0.7ml pf.syr (1 δοση)

sanofi pasteur, lyon, france 14 espace henry vallee, 69007 lyon - a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022, ivr-238); a/darwin/9/2021 (h3n2) - like strain a/darwin/9/2021, san-010); b/austria/1359417/2021 - like strain b/austria/1359417/2021, bvr-26); b/phuket/3073/2013 – like strain(b/phuket/3073/2013, wild type) - inj.su.pfs (ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΣΕ ΠΡΟΓΕΜΙΣΜΕΝΗ ΣΥΡΙΓΓΑ) - (60+60+60+60)mcg/0.7ml pf.syr (1 ΔΟΣΗ) - a/victoria/4897/2022 (h1n1) pdm09 - like strain (a/victoria/4897/2022, ivr-238) 60mcg; a/darwin/9/2021 (h3n2) - like strain a/darwin/9/2021, san-010) 60mcg; b/austria/1359417/2021 - like strain b/austria/1359417/2021, bvr-26) 60mcg; b/phuket/3073/2013 – like strain(b/phuket/3073/2013, wild type) 60mcg - influenza, purified antigen